Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3403 | Ruxolitinib Wiki | 0.32 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This study will evaluate the changes in sexual function, reproductive function and mental health of male patients discharged from the hospital with COVID-19, and the impact of SARS-CoV-2 on male reproductive health and mental health compared with healthy people during the same period. In addition, men's semen examination reports before and after the new coronavirus pneumonia event will be collected and compared to assess the impact of the event on the quality of men's semen. Also, This study will test the SARS-CoV-2 nucleic acid of the urogenital system of male patients discharged with COVID-19 to provide evidence for the effect of the new coronavirus on the male reproductive system.
Description: Sperm density will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.
Measure: Sperm density Time: 3 monthsDescription: Sperm activity will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.
Measure: Sperm activity Time: 3 monthsDescription: Erection hardness and duration will be evaluated during sleep by RigiscanHealth Organization (WHO) normal values based on the WHO 2010 reference limits.
Measure: Erection hardness and duration Time: 3 monthsDescription: IIEF-5/QEQ questionnaire score will be obtained by filling out the questionnaire every visit.
Measure: IIEF-5/QEQ questionnaire score Time: 3 monthsDescription: Detection rate of SARS-CoV-2 in male genitourinary system will be evaluated by real time-polymerase chain reaction (RT-PCR).
Measure: Detection rate of SARS-CoV-2 in male genitourinary system Time: 1 monthDescription: Sperm volume will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.
Measure: Semen volume Time: 3 monthsDescription: Sperm survival rate will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.
Measure: Sperm survival rate Time: 3 monthsDescription: The serum testosterone/LH/FSH levels will be tested in every visit.
Measure: Serum testosterone/luteinizing hormone (LH)/follicle stimulating hormone (FSH) level Time: 3 monthsDescription: SCL-90 questionnaire score will be obtained using SCL-90 questionnaire.
Measure: SCL-90 questionnaire score Time: 3 monthsDescription: Height will be measured at every visit
Measure: Height Time: 3 monthsDescription: Weight will be measured at every visit
Measure: Weight Time: 3 monthsDescription: Clinical classification of COVID-19 will be determined according to the New Coronavirus Pneumonia Prevention and Control Program (7th edition) published by the National Health Commission of China
Measure: Clinical classification of COVID-19 Time: 1 monthAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports